Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer

Research output: Contribution to journalArticle

Abstract

A correlation between osteopontin, E-cadherin, β-catenin, and cyclooxygenase 2 overexpression and poor clinicopathological features and prognosis has been previously suggested in gastric cancer. This translational study was aimed at assessing the correlation of these immunohistochemical biomarkers with outcome in patients with radically resected gastric cancer. We analyzed osteopontin, E-cadherin, β-catenin, and cyclooxygenase 2 expression by immunohistochemistry in 346 primary gastric tumor tissue samples from patients enrolled in the ITACA-S trial. This phase III study randomized patients with radically resected gastric cancer to receive adjuvant chemotherapy with either 5-fluorouracil and leucovorin or a sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel. High expression of osteopontin was correlated with high histological grade, diffuse histotype, and peritoneal relapse, but not with TNM stage. Moreover, osteopontin overexpression was associated with higher risk of tumor recurrence and metastases, and was an independent prognostic factor for both relapse-free and overall survival of gastric cancer patients following adjuvant chemotherapy. Abnormal E-cadherin expression and abnormal β-catenin expression were correlated with more advanced disease stage, and as a consequence, with poor outcome. Our results suggest that osteopontin overexpression is a valuable independent predictor of tumor recurrence and survival in patients with radically resected gastric cancer.

Original languageEnglish
JournalGastric Cancer
DOIs
Publication statusAccepted/In press - Apr 11 2015

Fingerprint

Catenins
Osteopontin
Cadherins
Stomach Neoplasms
Biomarkers
Recurrence
irinotecan
Leucovorin
docetaxel
Cyclooxygenase 2
Adjuvant Chemotherapy
Fluorouracil
Neoplasms
Survival
Cisplatin
Stomach
Immunohistochemistry
Neoplasm Metastasis

Keywords

  • Adjuvant chemotherapy
  • Biomarker
  • Gastric cancer
  • Osteopontin
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

@article{26a25c49ade4491ab0722d0dd9ccfeb0,
title = "Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer",
abstract = "A correlation between osteopontin, E-cadherin, β-catenin, and cyclooxygenase 2 overexpression and poor clinicopathological features and prognosis has been previously suggested in gastric cancer. This translational study was aimed at assessing the correlation of these immunohistochemical biomarkers with outcome in patients with radically resected gastric cancer. We analyzed osteopontin, E-cadherin, β-catenin, and cyclooxygenase 2 expression by immunohistochemistry in 346 primary gastric tumor tissue samples from patients enrolled in the ITACA-S trial. This phase III study randomized patients with radically resected gastric cancer to receive adjuvant chemotherapy with either 5-fluorouracil and leucovorin or a sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel. High expression of osteopontin was correlated with high histological grade, diffuse histotype, and peritoneal relapse, but not with TNM stage. Moreover, osteopontin overexpression was associated with higher risk of tumor recurrence and metastases, and was an independent prognostic factor for both relapse-free and overall survival of gastric cancer patients following adjuvant chemotherapy. Abnormal E-cadherin expression and abnormal β-catenin expression were correlated with more advanced disease stage, and as a consequence, with poor outcome. Our results suggest that osteopontin overexpression is a valuable independent predictor of tumor recurrence and survival in patients with radically resected gastric cancer.",
keywords = "Adjuvant chemotherapy, Biomarker, Gastric cancer, Osteopontin, Prognosis",
author = "{Di Bartolomeo}, Maria and Filippo Pietrantonio and Alessandro Pellegrinelli and Antonia Martinetti and Luigi Mariani and Daidone, {Maria Grazia} and Emilio Bajetta and Giuseppe Pelosi and {de Braud}, Filippo and Irene Floriani and Rosalba Miceli",
year = "2015",
month = "4",
day = "11",
doi = "10.1007/s10120-015-0495-y",
language = "English",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer

AU - Di Bartolomeo, Maria

AU - Pietrantonio, Filippo

AU - Pellegrinelli, Alessandro

AU - Martinetti, Antonia

AU - Mariani, Luigi

AU - Daidone, Maria Grazia

AU - Bajetta, Emilio

AU - Pelosi, Giuseppe

AU - de Braud, Filippo

AU - Floriani, Irene

AU - Miceli, Rosalba

PY - 2015/4/11

Y1 - 2015/4/11

N2 - A correlation between osteopontin, E-cadherin, β-catenin, and cyclooxygenase 2 overexpression and poor clinicopathological features and prognosis has been previously suggested in gastric cancer. This translational study was aimed at assessing the correlation of these immunohistochemical biomarkers with outcome in patients with radically resected gastric cancer. We analyzed osteopontin, E-cadherin, β-catenin, and cyclooxygenase 2 expression by immunohistochemistry in 346 primary gastric tumor tissue samples from patients enrolled in the ITACA-S trial. This phase III study randomized patients with radically resected gastric cancer to receive adjuvant chemotherapy with either 5-fluorouracil and leucovorin or a sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel. High expression of osteopontin was correlated with high histological grade, diffuse histotype, and peritoneal relapse, but not with TNM stage. Moreover, osteopontin overexpression was associated with higher risk of tumor recurrence and metastases, and was an independent prognostic factor for both relapse-free and overall survival of gastric cancer patients following adjuvant chemotherapy. Abnormal E-cadherin expression and abnormal β-catenin expression were correlated with more advanced disease stage, and as a consequence, with poor outcome. Our results suggest that osteopontin overexpression is a valuable independent predictor of tumor recurrence and survival in patients with radically resected gastric cancer.

AB - A correlation between osteopontin, E-cadherin, β-catenin, and cyclooxygenase 2 overexpression and poor clinicopathological features and prognosis has been previously suggested in gastric cancer. This translational study was aimed at assessing the correlation of these immunohistochemical biomarkers with outcome in patients with radically resected gastric cancer. We analyzed osteopontin, E-cadherin, β-catenin, and cyclooxygenase 2 expression by immunohistochemistry in 346 primary gastric tumor tissue samples from patients enrolled in the ITACA-S trial. This phase III study randomized patients with radically resected gastric cancer to receive adjuvant chemotherapy with either 5-fluorouracil and leucovorin or a sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel. High expression of osteopontin was correlated with high histological grade, diffuse histotype, and peritoneal relapse, but not with TNM stage. Moreover, osteopontin overexpression was associated with higher risk of tumor recurrence and metastases, and was an independent prognostic factor for both relapse-free and overall survival of gastric cancer patients following adjuvant chemotherapy. Abnormal E-cadherin expression and abnormal β-catenin expression were correlated with more advanced disease stage, and as a consequence, with poor outcome. Our results suggest that osteopontin overexpression is a valuable independent predictor of tumor recurrence and survival in patients with radically resected gastric cancer.

KW - Adjuvant chemotherapy

KW - Biomarker

KW - Gastric cancer

KW - Osteopontin

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84927555675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927555675&partnerID=8YFLogxK

U2 - 10.1007/s10120-015-0495-y

DO - 10.1007/s10120-015-0495-y

M3 - Article

AN - SCOPUS:84927555675

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

ER -